ATRC

AtriCure, Inc.

$56.26

-2.63%
SectorHealthcareIndustryMedical Instruments & SuppliesCountryUnited States

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation.

Source: Yahoo Finance
AI summary

Price & performance

1M+8.7%
3M+55.8%
YTD+56.0%
1Y+89.6%
52-week range—
Beta1.02
Full chart and returns against a benchmark

Q-Score

64/ 100

Quality against peers; 50 is the peer median.

Growth67
Risk61
Performance62
Valuation40
Profitability70
Leverage63
Sentiment38
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$534.5M+14.9%
Net income-$11.4M
Net margin-2.1%+7.5 pts
Historical fundamentals

Revenue exposure

19%of revenue from outside the US
United States81%
Europe12%
Asia Pacific6%
Regions, segments, customers and suppliers

Valuation

ATRCIndustryP/E192.4949.36P/S4.863.73EV/EBITDA94.6523.12P/B5.373.92PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 3next report, after the close
EPS estimate$0.01
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate